newsfilter
← Latest News
GlobeNewswire·

Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis

New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitisStudy aims to expand once-daily ZORYVE cream treatment